journal article·2026-07Open access

A Molecular Shielding Strategy to Develop Low Protein Binding, Renal Clearable Pan‐Cancer Near‐Infrared Probes

Li Xiang, Kailin Mooney, Mingchong Dai, Morgan R. Stewart, Samantha Holland, Michael I. Henderson, Samuel Drennan, Ramon F. Barajas, Jared M. Fischer, Adem Yildirim

Advanced Functional Materials· Volume 36· Issue 56

Abstract

ABSTRACT Near‐infrared (NIR) fluorescent heptamethine cyanine (HMC) dyes with intrinsic tumor‐targeting ability are promising probes for solid tumor detection. However, HMC dyes are typically amphiphilic molecules, leading to non‐specific binding to blood proteins, primarily albumin, following systemic administration. While albumin binding can extend blood circulation time and enhance tumor accumulation, it can also lead to significant healthy tissue uptake, resulting in low tumor‐to‐background signal ratios (TBR) and potential toxicity. Here, we report a molecular shielding strategy to prevent non‐specific protein binding of tumor‐targeting HMC dyes. We develop a rationally designed library of molecularly shielded NIR fluorescent probes based on a clinically approved HMC dye, indocyanine green (ICG). To shield non‐specific protein interactions of ICG, its sidechain is modified with varying numbers of charged amino acid residues, which transformed ICG into a low protein binding, renal‐clearable pan‐cancer targeting probe. These shielded ICG molecules showed strong tumor accumulation and optimal tissue clearance in a few days, enabling high‐contrast tumor imaging with TBR values reaching 8 and clear tumor margins in orthotopic rodent tumor models. These new tumor‐targeting NIR probes represent a clinically translatable platform for cancer detection and therapy with a modular molecular structure composed of non‐toxic, FDA‐approved components.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Sulfur Compounds in Biology · Luminescence and Fluorescent Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

CEDAR Knight Cancer Institute School of Medicine Oregon Health and Science University Portland Oregon USA

Neuro‐Oncology Blood‐Brain Barrier Program Oregon Health and Science University Portland Oregon USA

Department of Radiology School of Medicine Oregon Health and Science University Portland Oregon USA

Department of Biomedical Engineering School of Medicine Oregon Health and Science University Portland Oregon USA

Advanced Imaging Research Center Oregon Health and Science University Portland Oregon USA

Knight Cancer Institute School of Medicine Oregon Health and Science University Portland Oregon USA

Department of Molecular and Medical Genetics School of Medicine Oregon Health and Science University Portland Oregon USA

Division of Oncological Sciences Knight Cancer Institute School of Medicine Oregon Health and Science University Portland Oregon USA

References (76)

Show source-provided references
1. 10.1038/s44222‐022‐00002‐810.1038/s44222‐022‐00002‐8 ↗
2. 10.1021/acs.chemrev.3c0077610.1021/acs.chemrev.3c00776 ↗
3. 10.1039/C3CS60271K10.1039/C3CS60271K ↗
4. 10.1038/nrclinonc.2013.12310.1038/nrclinonc.2013.123 ↗
5. 10.1038/s44222‐022‐00017‐110.1038/s44222‐022‐00017‐1 ↗
6. 10.1038/s41571‐021‐00548‐310.1038/s41571‐021‐00548‐3 ↗
7. 10.1227/NEU.000000000000034410.1227/NEU.0000000000000344 ↗
8. 10.3389/fbioe.2021.76869810.3389/fbioe.2021.768698 ↗
9. 10.1038/nrclinonc.2016.21210.1038/nrclinonc.2016.212 ↗
10. 10.1016/j.cbpa.2021.10211210.1016/j.cbpa.2021.102112 ↗
11. 10.1039/D4BM00410H10.1039/D4BM00410H ↗
12. Precision Surgery Guided by Intraoperative Molecular Imaging
13. 10.1038/s41467-022-29630-910.1038/s41467-022-29630-9 ↗
14. 10.1038/s41598‐021‐84831‐410.1038/s41598‐021‐84831‐4 ↗
15. 10.1039/C9SC02197C10.1039/C9SC02197C ↗
16. 10.2147/IJN.S20310810.2147/IJN.S203108 ↗
17. 10.1002/anie.20200979610.1002/anie.202009796 ↗
18. 10.1021/acs.molpharmaceut.7b0082210.1021/acs.molpharmaceut.7b00822 ↗
19. 10.1200/JCO.22.0029110.1200/JCO.22.00291 ↗
20. 10.1001/jamasurg.2022.107510.1001/jamasurg.2022.1075 ↗
21. 10.1007/s11307‐021‐01614‐z10.1007/s11307‐021‐01614‐z ↗
22. 10.1021/acsnano.3c0356410.1021/acsnano.3c03564 ↗
23. 10.1158/1078‐0432.CCR‐19‐168610.1158/1078‐0432.CCR‐19‐1686 ↗
24. 10.1038/bjc.2012.58110.1038/bjc.2012.581 ↗
25. 10.1093/neuonc/noac20410.1093/neuonc/noac204 ↗
26. 10.1158/1078‐0432.CCR‐10‐005910.1158/1078‐0432.CCR‐10‐0059 ↗
27. 10.1016/j.biomaterials.2011.06.02410.1016/j.biomaterials.2011.06.024 ↗
28. 10.1016/j.biomaterials.2011.11.08110.1016/j.biomaterials.2011.11.081 ↗
29. 10.1016/j.biomaterials.2012.11.05710.1016/j.biomaterials.2012.11.057 ↗
30. 10.1016/j.biomaterials.2013.10.03310.1016/j.biomaterials.2013.10.033 ↗
31. 10.1016/j.biomaterials.2014.05.07310.1016/j.biomaterials.2014.05.073 ↗
32. 10.1117/1.JBO.21.5.05090110.1117/1.JBO.21.5.050901 ↗
33. 10.1155/2013/86353910.1155/2013/863539 ↗
34. 10.1016/j.biomaterials.2015.07.02810.1016/j.biomaterials.2015.07.028 ↗
35. 10.18632/oncotarget.246410.18632/oncotarget.2464 ↗
36. 10.1021/acs.bioconjchem.9b0077110.1021/acs.bioconjchem.9b00771 ↗
37. 10.1002/adma.20231151510.1002/adma.202311515 ↗
38. 10.1038/s41578‐021‐00328‐610.1038/s41578‐021‐00328‐6 ↗
39. 10.1002/anie.20210264010.1002/anie.202102640 ↗
40. 10.1039/C6SC05059J10.1039/C6SC05059J ↗
41. 10.1155/2012/94058510.1155/2012/940585 ↗
42. 10.1177/155335061560405310.1177/1553350615604053 ↗
43. 10.1117/12.18493610.1117/12.184936 ↗
44. 10.1016/S0039‐6257(00)00123‐510.1016/S0039‐6257(00)00123‐5 ↗
45. Binding Properties of Indocyanine Green in Human Blood
46. 10.1021/acs.bioconjchem.6b0011710.1021/acs.bioconjchem.6b00117 ↗
47. 10.1021/acs.analchem.6b0097610.1021/acs.analchem.6b00976 ↗
48. 10.1016/j.ejps.2015.05.00810.1016/j.ejps.2015.05.008 ↗
49. 10.1002/anie.20201018710.1002/anie.202010187 ↗
50. 10.1002/chem.20210281610.1002/chem.202102816 ↗
51. 10.1080/10717544.2019.158273010.1080/10717544.2019.1582730 ↗
52. 10.1016/j.jconrel.2010.05.02310.1016/j.jconrel.2010.05.023 ↗
53. 10.1002/mabi.20170030910.1002/mabi.201700309 ↗
54. 10.1007/s10867‐008‐9074‐310.1007/s10867‐008‐9074‐3 ↗
55. 10.1021/jacs.8b0658410.1021/jacs.8b06584 ↗
56. 10.1021/nn100816s10.1021/nn100816s ↗
57. 10.1021/acs.molpharmaceut.7b0061110.1021/acs.molpharmaceut.7b00611 ↗
58. 10.1021/jm300212s10.1021/jm300212s ↗
59. 10.1096/fj.201700767R10.1096/fj.201700767R ↗
60. 10.3390/molecules2412229510.3390/molecules24122295 ↗
61. 10.1186/s12951‐020‐00603‐810.1186/s12951‐020‐00603‐8 ↗
62. 10.1055/s‐0028‐109061710.1055/s‐0028‐1090617 ↗
63. 10.1002/adma.20250935910.1002/adma.202509359 ↗
64. 10.1038/s41598-017-13437-610.1038/s41598-017-13437-6 ↗
65. Fluorescence Image‐Guided Surgery: A Perspective on Contrast Agent Development
66. 10.4254/wjh.v8.i7.35510.4254/wjh.v8.i7.355 ↗
67. 10.1021/acsnano.5b0132010.1021/acsnano.5b01320 ↗
68. 10.1021/acsnano.3c0585310.1021/acsnano.3c05853 ↗
69. 10.2133/dmpk.19.17110.2133/dmpk.19.171 ↗
70. 10.1124/dmd.113.05478310.1124/dmd.113.054783 ↗
71. 10.1002/ijc.3010210.1002/ijc.30102 ↗
72. 10.1021/acsabm.0c0009110.1021/acsabm.0c00091 ↗
73. 10.1117/1.NPh.11.2.02420610.1117/1.NPh.11.2.024206 ↗
74. 10.1016/j.lfs.2014.10.00610.1016/j.lfs.2014.10.006 ↗
75. 10.1016/j.mam.2012.02.00310.1016/j.mam.2012.02.003 ↗
76. 10.1093/noajnl/vdac16610.1093/noajnl/vdac166 ↗